{"title":"Gender Dysphoria & Dissociative Identity Disorder in Autism Spectrum Disorder.","authors":"Snigdha Nandipati, Anuradha Reddy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This patient is a 17 year old Caucasian transgender male (FTM) with autism spectrum disorder (ASD level 1), gender dysphoria (GD), and dissociative identity disorder (DID). The patient has multiple psychiatric comorbidities including obsessive-compulsive disorder (OCD), generalized anxiety disorder (GAD), attention-deficit hyperactivity disorder (ADHD), emotional dysregulation, trauma and stressor disorder, and insomnia. Medical comorbidities include 16p13.3 and 16p24.3 microdeletions, hypotonia, bilateral cataracts (surgically corrected), and minimal change disease. To our knowledge, this is the first case report in which the patient is suffering from ASD, GD, and DID as comorbid diagnoses. Our review of this patient serves to highlight the complexity of providing care to patients with a comorbidity of ASD, GD, and DID, as well as the complexity in distinguishing these conditions from one another.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 4","pages":"104-109"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233935/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593298","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Contraception and Mood Effects-<i>Untended or Unintended?</i>","authors":"Ahmed Naguy, Bibi Alamiri","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Authors herein decently argue that psychiatrists can and should play a crucial role in helping women understand the interplay of reproductive health and mental health as they are positioned to be an advocate as well as an active force in enabling reproductive choice.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 4","pages":"133-135"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233945/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Genital Dysmorphia-<i>A Valid Diagnostic Construct?</i> and Psychopharmacological Options at Hand.","authors":"Ahmed Naguy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Genital dysmorphia, with male preponderance, is commonly used to refer to penile dysmorphia. This dysmorphia, centred on penile size, can be contextualized as a specifier of body dysmorphic disorder with varied levels of insight. It follows that cosmetic surgery for men with genital dysmorphia without prior assessment and specific treatment is unlikely to be helpful.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 4","pages":"127-129"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144593299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alyssa H Sze, Akhil S Pola, Amanda G Smith, Jay Vora, Michael P Greenage
{"title":"A Case of Clozapine Induced Mania-Like Symptoms in the Treatment of Schizophrenia.","authors":"Alyssa H Sze, Akhil S Pola, Amanda G Smith, Jay Vora, Michael P Greenage","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Clozapine is an atypical antipsychotic and is the drug of choice for treatment-resistant schizophrenia. Unlike other atypical antipsychotics which are known to occasionally cause symptoms of mania or hypomania, clozapine has been shown to be effective at symptom reduction during manic episodes in treatment-resistant bipolar disorder and is generally well tolerated in those severe mood disorders. To our knowledge, there is only one other reported case of potential clozapine-induced mania. In this case report and review, we present a 47-year-old caucasian male with a well-established history of schizophrenia who was voluntarily admitted to an inpatient psychiatric unit for paranoia and auditory hallucinations. The patient had trialed multiple antipsychotics prior to the current hospitalization, with the exception of clozapine. To our knowledge, this is the second case report of manic-like symptoms that may be secondary to clozapine.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"56-59"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144061815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri
{"title":"Quetiapine and Paediatric Psychiatrica: <i>Evidence or Diffidence?</i>","authors":"Ahmed Naguy, Saxby Pridmore, Hend Fm Fr Alenezi, Bibi Alamiri","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The atypical antipsychotic, quetiapine has been on market for years now with long track record. In child and adolescent psychiatry, it is FDA-approved for childhood-onset schizophrenia and juvenile bipolar mood disorder. Its attractive pharmacological portfolio speaks to the idea of a versatile pluripotent broad-spectrum psychotropic agent expanding its therapeutic potential on clinical grounds. In this focussed review, authors brief these clinical indications whilst examining the extant evidence.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"31-36"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983474/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Akinetic Mutism Following Bilateral Infarcts Associated with a Mitral Valve Papillary Fibroelastoma.","authors":"Stanley Lyndon","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Akinetic mutism is a rare but important clinical syndrome characterised by a profound decrease in goal-directed behaviour and speech output, yet with preservation of consciousness. This report describes the case of a 58-year-old male with a background of hypertension, alcohol use disorder, smoking, and MTHFR C677T homozygosity who experienced two ischaemic strokes within weeks of each other. The initial infarct involved the right thalamus, posterior putamen, external capsule, and subcortical anterior frontal lobe. Approximately five weeks later, he developed a second stroke in the left hemisphere, eventually leading to the identification of a mitral valve mass consistent with a papillary fibroelastoma. Following surgical resection of this mass, the patient demonstrated severe reductions in spontaneous movement and speech in a pattern consistent with akinetic mutism. He ultimately improved with rehabilitative measures and the initiation of a stimulant medication. This case highlights the intricate relationship between bilateral frontal-subcortical network injuries and the development of akinetic mutism.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"37-43"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983479/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144036581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A Musso
{"title":"Electroconvulsive Therapy, Ketamine, and Esketamine in a Patient with Major Depressive Disorder and Multiple Comorbidities: A Case Report over 10-year Treatment from Adolescence to Adulthood.","authors":"Keming Gao, Buket Koparal, Evrim Bayrak Oruc, Margret A Musso","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In this case report, we present a patient with treatment-resistant depression (TRD) and comorbid generalized anxiety disorder, eating disorder, post-traumatic stress disorder, and borderline personality disorder. Over a 10-year period, our case transitioned from adolescence to adulthood and received antidepressant monotherapy, adjunctive therapy with antipsychotics, lithium, or lamotrigine, several series of electroconvulsive therapy (ECT), ketamine infusion (KET-IFU), compounded ketamine intranasal spray (COM-KET), and intranasal esketamine (ESK). She had seventeen documented hospitalizations, five self-reported hospitalizations, three intensive outpatient program treatments, two partial hospitalization program treatments, and three residential treatments. She attempted suicide seven times. She received five acute ECT series, one series of KET-IFU, one series of acute ESK with weekly ECT, a series of COM-KET treatment for more than two years, and a series of ESK for more than two years. The patient had some short-term benefit from ECT and KET-IFU. However, she had two-years stability with COM-KET or ESK at two different times. She has been relatively stable without hospitalization or suicide attempt with ESK for more than two years, suggesting that patients with TRD with complex representations may benefit from ketamine treatment at different times of life development.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"44-55"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144049596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Incretin Mimetics (GLP-1 Agonists) as an Addition to the Psychopharmacology Armamentarium.","authors":"Hend Fm Fr Alenezi, Ahmed Naguy","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The exploration of GLP-1 receptor agonists as pleiotropic agents in the treatment of neuropsychiatric disorders and substance use disorders is a rapidly evolving field. While early studies have shown promising results, much of the research is still nascent, and larger clinical trials are definitely needed to confirm the safety and efficacy of these agents on real grounds.</p>","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"55 3","pages":"26-30"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11983476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047526","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}